INXMED
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.
INXMED
Social Links:
Industry:
Biotechnology Life Science
Founded:
2018-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.en.inxmed.com
Total Employee:
11+
Status:
Active
Contact:
+0086-21-50630108
Email Addresses:
[email protected]
Total Funding:
94 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Mobile Non Scaleable Content Euro Microsoft Exchange Online Office 365 Mail IPv6 Pound Sterling
Similar Organizations
Alebund Pharmaceuticals
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases.
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
AUM Biosciences
AUM Biosciences is committed to addressing the unmet medical needs by developing innovative and affordable oncology therapeutics for Asia.
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
Nectin Therapeutics
Nectin Therapeutics is a startup company dedicated to the development of next generation immuno-oncology antibodies.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Visen Pharmaceuticals
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
SPD Silicon Valley Bank (SSVB)
SPD Silicon Valley Bank (SSVB) investment in Debt Financing - InxMed
Hyfinity Investments
Hyfinity Investments investment in Series B - InxMed
Ennovation Ventures
Ennovation Ventures investment in Series B - InxMed
AIHC Capital
AIHC Capital investment in Series B - InxMed
CS Capital
CS Capital investment in Series B - InxMed
HosenCare Brothers
HosenCare Brothers investment in Series B - InxMed
Ennovation Ventures
Ennovation Ventures investment in Series A - InxMed
China Growth Capital | CGC
China Growth Capital | CGC investment in Series A - InxMed
InnoMed Capital
InnoMed Capital investment in Series A - InxMed
Grand Yangtze Capital
Grand Yangtze Capital investment in Series A - InxMed
Official Site Inspections
http://www.en.inxmed.com
- Host name: server-13-225-63-47.ewr53.r.cloudfront.net
- IP address: 13.225.63.47
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "InxMed"
About_InxMed-Leading Innovations Targeting Tumor Defense
About-InxMed-Leading Innovations Targeting Tumor DefenseInxMed is a clinical-stage biotech company established in 2018. The company is dedicated to developing innovative therapies …See details»
Overview_InxMed-Leading Innovations Targeting Tumor Defense
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid …See details»
InxMed - Overview, News & Similar companies | ZoomInfo.com
Dec 20, 2023 Who is InxMed. InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting strom a …See details»
InxMed Company Profile 2024: Valuation, Funding
InxMed General Information Description. Developer of cancer therapeutics designed to treat cancer. The company currently has pharmaceuticals targeting pancreatic, ovarian, gastric and other forms of cancer, enabling healthcare …See details»
InxMed - Crunchbase Company Profile & Funding
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are …See details»
InxMed Co, Ltd - VentureRadar
"InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid …See details»
InxMed Company Profile - Office Locations, Competitors, Revenue …
InxMed (应世生物) is a clinical-stage biotechnology company that develops individualized medicines. It builds up a differentiated drug pipeline with the potential of intrinsic synergy to …See details»
Inxmed - Company Profile - Tracxn
Oct 31, 2024 Inxmed - Developer of treatments for drug resistance and metastases in solid tumors. Raised a total funding of $84M over 4 rounds from 10 investors. Founded by Francis …See details»
InxMed - Products, Competitors, Financials, Employees, …
InxMed was founded in 2017. Where is InxMed's headquarters? InxMed's headquarters is located at 3007, 30th Floor, Block 2, China Central Place Office Building, No.79 Jianguo Road, …See details»
InxMed raises $15m to advance development of cancer therapies
May 9, 2022 InxMed is a clinical-stage biotechnology company engaged in developing medicines that target stroma microenvironment and drug resistance for hard-to-treat solid …See details»
Our Science_InxMed-Leading Innovations Targeting Tumor Defense
Our Science-InxMed-Leading Innovations Targeting Tumor DefenseInxMed is a clinical-stage biotech company established in 2018. The company is dedicated to developing innovative …See details»
GeneQuantum and InxMed have reached a technology licensing ...
InxMed has established translational medicine and clinical teams at Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada and Australia. Through independent …See details»
James McLeod - Chief Medical Officer, USA at InxMed - The Org
James Mc Leod is a physician scientist and pharmaceutical executive with over 25 years of experience spanning preclinical and the phases of clinical development. Prior to joining …See details»
IN-30728 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 IN-30728, Initially developed by Inxmed (Nanjing) Co., Ltd, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Solid ...See details»
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy ...
Nov 21, 2024 Established in 2018, InxMed has built an efficient engine for clinical translational research driven by an in-depth understanding of disease biology. InxMed's pipeline includes …See details»
History_InxMed-Leading Innovations Targeting Tumor Defense
History-InxMed-Leading Innovations Targeting Tumor DefenseInxMed is a clinical-stage biotech company established in 2018. The company is dedicated to developing innovative therapies …See details»
InxMed Raised $15 million in Series B+ Financing to Advance …
May 9, 2022 InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment …See details»
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy ...
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, …See details»
Company News_Press Release_InxMed-Leading Innovations …
EN CN About Us. Overview ... News Center 04. 2024-06. 2024-06-04 InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung …See details»